Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) EBIT (2016 - 2025)

Historic EBIT for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$164.7 million.

  • Viking Therapeutics' EBIT fell 25628.27% to -$164.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$393.3 million, marking a year-over-year decrease of 16062.77%. This contributed to the annual value of -$393.3 million for FY2025, which is 16062.77% down from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' EBIT is -$164.7 million, which was down 25628.27% from -$98.6 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year EBIT high stood at -$12.5 million for Q4 2021, and its period low was -$164.7 million during Q4 2025.
  • Moreover, its 5-year median value for EBIT was -$25.5 million (2023), whereas its average is -$38.6 million.
  • In the last 5 years, Viking Therapeutics' EBIT crashed by 1104.21% in 2021 and then plummeted by 25628.27% in 2025.
  • Viking Therapeutics' EBIT (Quarter) stood at -$12.5 million in 2021, then plummeted by 62.13% to -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then crashed by 256.28% to -$164.7 million in 2025.
  • Its EBIT stands at -$164.7 million for Q4 2025, versus -$98.6 million for Q3 2025 and -$74.6 million for Q2 2025.